norfloxacin has been researched along with Corynebacterium Infections in 4 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
Corynebacterium Infections: Infections with bacteria of the genus CORYNEBACTERIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral doses of norfloxacin (80 mg/kg of body weight per day) and ciprofloxacin (25 and 80 mg/kg/day) and intramuscular doses of teicoplanin (5 mg/kg/day), all administered once a day for 10 days, were evaluated as a means of preventing encrusted cystitis caused by Corynebacterium group D2." | 7.68 | Treatment of encrusted cystitis caused by Corynebacterium group D2 with norfloxacin, ciprofloxacin, and teicoplanin in an experimental model in rats. ( Avilés, P; Castilla, C; Rodriguez-Tudela, JL; Soriano, F, 1991) |
| "Oral doses of norfloxacin (80 mg/kg of body weight per day) and ciprofloxacin (25 and 80 mg/kg/day) and intramuscular doses of teicoplanin (5 mg/kg/day), all administered once a day for 10 days, were evaluated as a means of preventing encrusted cystitis caused by Corynebacterium group D2." | 3.68 | Treatment of encrusted cystitis caused by Corynebacterium group D2 with norfloxacin, ciprofloxacin, and teicoplanin in an experimental model in rats. ( Avilés, P; Castilla, C; Rodriguez-Tudela, JL; Soriano, F, 1991) |
| " Among quinolones, the most active agents are ciprofloxacin and ofloxacin (MIC modes: 4 and 2 mg/l), so these antimicrobials could be used for the treatment of urinary tract infections caused by Corynebacterium group D2." | 3.67 | [Corynebacterium group D2. Clinical study, biochemical identification and antibiotic sensitivity]. ( Cancet, B; Clave, D; Didier, J; Henry-Ferry, S; Marty, N, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vedel, G | 1 |
| Toussaint, G | 1 |
| Riegel, P | 1 |
| Fouilladieu, JL | 1 |
| Billöet, A | 1 |
| Poyart, C | 1 |
| Soriano, F | 2 |
| Rodriguez-Tudela, JL | 2 |
| Castilla, C | 1 |
| Avilés, P | 2 |
| Fernández-Roblas, R | 1 |
| Zapardiel, J | 1 |
| Romero, M | 1 |
| Marty, N | 1 |
| Clave, D | 1 |
| Cancet, B | 1 |
| Henry-Ferry, S | 1 |
| Didier, J | 1 |
4 other studies available for norfloxacin and Corynebacterium Infections
| Article | Year |
|---|---|
Corynebacterium pseudogenitalium urinary tract infection.
Topics: Anti-Bacterial Agents; Corynebacterium; Corynebacterium Infections; Humans; Male; Middle Aged; Norfl | 2006 |
Treatment of encrusted cystitis caused by Corynebacterium group D2 with norfloxacin, ciprofloxacin, and teicoplanin in an experimental model in rats.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Corynebacterium Infections; Cystitis; Female; Glycope | 1991 |
Increasing incidence of Corynebacterium group D2 strains resistant to norfloxacin and ciprofloxacin.
Topics: Ciprofloxacin; Corynebacterium; Corynebacterium Infections; Drug Resistance, Microbial; Humans; Norf | 1989 |
[Corynebacterium group D2. Clinical study, biochemical identification and antibiotic sensitivity].
Topics: Anti-Bacterial Agents; Ciprofloxacin; Corynebacterium; Corynebacterium Infections; Drug Resistance, | 1988 |